- Use of any approved tyrosine kinase inhibitors or investigational agents within 2 weeks or 6 half-lives of the agent, whichever is shorter, prior to receiving study drugs. Treatment-related adverse events must have resolved or reduced to Grade 1 prior to enrollment.